JCJun Chen

Jun Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Chen has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liver CT-based composite biomarkers can identify MASH and steatosis grade in people with obesity prior to bariatric surgery: a retrospective study

    by Hailong Zhang, Zhuoru Jiang, Huanhuan Zheng, Haoyao Wang, Liankun Xia, Jun Chen, Bing Zhang

    Background: Hepatic steatosis is a precursor to metabolic dysfunction-associated steatohepatitis (MASH), which is linked to obesity and diabetes and poses a risk for liver cirrhosis and cancer. For detecting MASH and hepatic steatosis, liver biopsy is the reference method, but it is invasive and impractical for repeated monitoring of treatment efficacy. Our goal was to develop a convenient and non-invasive tool for accurately identifying MASH and steatosis grade in people with obesity. Methods: This retrospective study included 321 people with obesity who underwent bariatric surgery, during which liver biopsies were also performed. Clinical characteristics, presurgical computed tomography (CT)-derived parameters, magnetic resonance imaging proton density fat fraction (MRI-PDFF), and CT-based skeletal muscle index (SMI) were obtained. Results: A convenient model consisting of liver CT attenuation value (CT Liver ), alanine aminotransferase (ALT) and high-density lipoprotein cholesterol (HDL-C) was developed for identifying MASH, with area under the curve (AUC) of 0.799. To predict hepatic steatosis of grade ≥ 1, ≥ 2 and 3, the AUCs of CT Liver -based combination models were 0.954, 0.927, and 0.894, respectively. The diagnostic performance of the CT Liver -based combination models was comparable to that of liver MRI-PDFF in identifying different hepatic steatosis grades (Delong’s test, p > 0.05). CT-based SMI was significantly positively correlated with hepatic steatosis grade ( r = 0.12, p = 0.031) and non-alcoholic fatty liver disease (NAFLD) activity score ( r = 0.18, p = 0.002). Conclusions: The liver CT-based composite biomarkers can identify MASH and hepatic steatosis grade with high diagnostic performance in people with obesity, providing a non-invasive, accessible, and practical supplementary tool for clinical stratified management.


  • Top Cited Papers
    Open Access

    Multi-modal AI for opportunistic screening, staging and progression risk stratification of steatotic liver disease

    by Yuan Gao, Chunli Li, Wanxing Chang, Bai Du, Xianghua Ye, Yee Hui Yeo, Yingda Xia, Heng Guo, Xiaoming Zhang, Wei Liu, et al.

    The global rise in steatotic liver disease poses a significant public health challenge. While non-contrast computed tomography scans hold promise for opportunistic detection of steatotic liver disease, their potential for staging and risk assessment remains underexplored. Here we present a multimodal AI model trained on a large dataset, comprising of (n=968) histopathologically and (n=1103) radiologically confirmed cases, validated against both histology (n=660) and MRI-PDFF (n=375) gold standards, demonstrating high accuracy in detecting mild to severe steatosis (AUC: 0.904-0.929) and clinically significant fibrosis (AUC: 0.824-0.888). Furthermore, integrating the model into the standard clinical pathway improves primary risk screening in a retrospective patient cohort (n=1192), identifying 36% more patients at risk of fibrosis progression. Using Cox proportional hazard model, we observe that the intermediate-high risk patients identified by the optimized clinical pathway exhibits a significantly higher incidence of cirrhosis (hazard ratio: 5.54: 2.69-11.42), showcasing the model's potential for early detection and management of steatotic liver disease.


  • 3D vector MR elastography applications in small organs

    by Vitaliy Atamaniuk, Łukasz Hańczyk, Jun Chen, Andrii Pozaruk, Marzanna Obrzut, Krzysztof Gutkowski, Wojciech Domka, Marian Cholewa, Richard L. Ehman, Bogdan Obrzut


  • 3D MR elastography-based stiffness as a marker for predicting tumor grade and subtype in cervical cancer

    by Yuanqiang Xiao, Wenying Chen, Xi Long, Mengsi Li, Lina Zhang, Chang Liu, Ying Deng, Chao Li, Bingjun He, Jun Chen, et al.


  • Open Access

    Neuroimaging associations with spatial navigation impairment in Alzheimer’s disease continuum: A narrative review

    by Qian Chen, Futao Chen, Cong Long, Jiaming Lu, Jiu Chen, Jun Chen, Zuzana Nedelska, Jakub Hort, Bing Zhang

    Identifying individuals with incipient Alzheimer’s disease (AD) are critical for early and targeted intervention before the dementia develops as AD progresses. Recently, emerging data have suggested that spatial navigation and neuroimaging could be utilized to identify individuals with prodromal AD. Compared to episodic memory, spatial navigation has fewer cultural and educational discrepancies and could serve as a promising marker for diagnosis and outcome measures in multicenter longitudinal studies with large cohorts. Furthermore, neuroimaging studies have contributed to our understanding of the structural and functional neural basis underlying spatial navigation and provided sensitive and non-invasive neuroimaging markers. The current review summarizes neuroimaging associations with spatial navigation impairment in the AD continuum, their potential pathophysiological mechanisms, and nonpharmacological interventions for spatial navigation impairments. We highlight the promising role of spatial navigation in the early identification of the preclinical and prodromal patients with potential risk of developing AD dementia. Multicenter large-scale longitudinal studies on patients across the AD continuum coupled with a standardized routine assessment of spatial navigation abilities in clinical settings are needed. This review may have implications for clinical practice and future research directions.


  • Open Access

    PNPLA3 Single Nucleotide Polymorphism Prevalence and Association with Liver Disease in a Diverse Cohort of Persons Living with HIV

    by Kenneth E. Sherman, Susan D. Rouster, Heidi Meeds, Javier Tamargo, Jun Chen, Richard Ehman, Marianna Baum

    In persons living with HIV (PLWH), there are multiple sources of liver injury. Gene polymorphisms of PNPLA3 (patatin-like phospholipase domain-containing protein 3) have been identified as an important cofactor for increased disease severity in both alcoholic and non-alcoholic steatohepatitis (NASH). We utilized a well-characterized cohort of ethnically and racially diverse patients with HIV to define the prevalence of PNPLA3 SNPs (single nucleotide polymorphism) (rs738409), and to determine the relationship to hepatic steatosis and liver fibrosis. Steatosis was determined using MRI-PDFF (magnetic resonance imaging-determined proton density fat fraction) and fibrosis was estimated using MR Elastography (MRE). From the Miami Area HIV Study (MASH) cohort, 100 HIV positive participants and 40 controls (HCV/HIV = 20; HCV and HIV negative = 20) were evaluated. Nearly 40% of all participants carried the variant G allele associated with increased liver disease severity and 5% were homozygotic GG. The variant SNP occurred most frequently in those self-identified as Hispanic compared to white or Black participants. Hepatic steatosis (>5% fat) was present significantly more often in those without HIV vs. those with (p < 0.001). Putative NAFLD/NASH was found to be present in 6% of tested subjects, who were HIV monoinfected. BMI was lower in those that carried the G allele for PNPLA3. This finding suggests that PNPLA3 may be an independent component to NAFLD (non-alcoholic fatty liver disease)/NASH development and longitudinal follow-up of the cohort is warranted.


  • Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort

    by Marianna K. Baum, Javier A. Tamargo, Richard L. Ehman, Kenneth E. Sherman, Jun Chen, Qingyun Liu, Raul N. Mandler, Colby Teeman, Sabrina S. Martinez, Adriana Campa


  • Static and dynamic liver stiffness: An ex vivo porcine liver study using MR elastography

    by Chun Yang, Meng Yin, Kevin J. Glaser, Xiangyang Zhu, Kai Xu, Richard L. Ehman, Jun Chen


  • Uterine fibroids: correlations between MRI appearance and stiffness via magnetic resonance elastography

    by Danielle E. Jondal, Jin Wang, Jun Chen, Krzysztof R. Gorny, Joel Felmlee, Gina Hesly, Shannon Laughlin-Tommaso, Elizabeth A. Stewart, Richard Ehman, David A. Woodrum

    Rationale and objectives Magnetic resonance elastography has proven to be a valuable tool in the diagnosis of liver fibrosis, breast and cervical cancer, but its application in uterine fibroids requires further characterization. The aim of the present study was to examine the relationship between uterine fibroid stiffness by MRE and MR imaging characteristics. Materials and methods An IRB-approved, HIPAA compliant review was performed of prospectively collected pelvic MRI and 2D-MRE data in patients with symptomatic uterine fibroids (N = 102). T1 and T2 weighted pelvic MRI with gadolinium enhancement were performed. In a small patient subset, fibroid stiffness was assessed by both 2D and 3D MRE. Fibroid stiffness by modality or imaging characteristics was analyzed using one-way analysis of variance followed by Student t test. Results Four fibroid groups were identified based on T2 appearance: Isointense (N = 7), bright (N = 6), dark with minimal heterogeneity (N = 69), and dark with substantial heterogeneity (N = 20). Mean fibroid stiffness was 4.81 ± 2.12 kPa. Comparison of fibroid stiffness by T2 signal intensity showed that T2 bright fibroids were significantly less stiff than fibroids appearing T2 dark with minimal heterogeneity (mean stiffness difference = 2.38 kPa; p < 0.05) and T2 dark fibroids with substantial heterogeneity were significantly less stiff than T2 dark fibroids with minimal heterogeneity (mean difference = 1.25 kPa; p < 0.05). There was no significant association between fibroid stiffness and T1 signal characteristics or gadolinium enhancement. There was no significant difference in stiffness values obtained by either 2D vs. 3D MRE. Conclusions These data suggest differences in fibroid stiffness are associated with different T2 imaging characteristics with less stiff fibroids being T2 bright and more stiff fibroids being T2 dark. Further studies are needed to determine if fibroid stiffness by MRE may serve as an imaging biomarker to help predict MR-guided treatment response.


  • Quantification of regional aortic stiffness using MR elastography: A phantom and ex-vivo porcine aorta study

    by Nan Zhang, Jun Chen, Meng Yin, Kevin J. Glaser, Lei Xu, Richard L. Ehman